Enrichment Program

The RCLD conducts a well-established and highly successful enrichment program through our seminar series, annual symposium and meetings of Special Interest Groups of our Themes.

Goals of the enrichment program are to:

  1. Organize and support a seminar series, which provides an educational forum to expose Center members and their staff to cutting edge science relevant to the themes of the Center.
  2. Support an Annual Symposium to facilitate interactions with and feedback from the External Scientific Advisory Board and the constructive review and monitoring of P/F projects.
  3. Provide a forum for mentoring and enhancement of collaborations through research-in-progress presentations and poster sessions, which provide junior faculty and trainees with feedback and established investigators with an opportunity to discuss roadblocks in the progress of their work and provide critical review of their studies.
  4. Develop a SIG specific minisymposium/workshop to promote collaborations within the SIG by inviting non-USC leaders in the field.

Director: Andrew Stolz, MD

Dr. Stolz is an Associate Professor of Medicine and his research focuses on drug induced liver injury (DILI) and alcoholic liver disease, with an interest in alcoholic hepatitis.

Current Enrichment Activities

Weekly Seminar Series

Jonathan Kaunitz, University of California, Los Angeles, “The gut-liver axis: Portal to systemic inflammation”
Bangyan Stiles, University of Southern California, “Lipid metabolism and liver cancer: Lessons from the PTEN model”

Spring Annual Mini-Symposium: To be announced.

Past Research Seminars (2018-2019)

Mengwei Zang, University of Texas Health Science Center at San Antonio, “Nutrient sensors: Linking metabolic regulation to fatty liver disease.”
Chise Tateno-Mukaidani, Phoenixbio Co., Ltd., Novel chimeric mice with human hepatocytes using cDNA-uPA/SCID mice and human hepatocytes isolated from chimeric mice.”
Peter Turnbaugh, University of San Francisco, “Microbiome mediators of dietary and pharmaceutical interventions.”
Shuping Zhong, Keck School of Medicine of USC, “Molecular mechanism of alcohol-associated human cancers.”
Naranbaatar D. Dashdorj, OMOM Foundation, “The hepatitis prevention, control and elimination program in Mongolia: A global model for hepatitis elimination.”
Jerzy W. Kupiec-Weglinski, David Geffen School of Medicine at UCLA, “ischemia-reperfusion injury in liver transplantation: New mechanistic insights and therapeutic opportunities.”
Scott Q. Siler, DILIsymServices, “Using quantitative systems pharmacology to increase the understanding of DILI and NAFLD.”
Lucy Golden, Keck School of Medicine of USC, “Natural killer cells and liver disease.”
Rohit Loomba, University of California, San Diego, “Novel advances in non-invasive imaging assessment in NASH trials.” NAST NAT”
Shiv K. Sarin, Jawahar Lal University, “Acute on chronic liver failure.” (Telfer Reynold’s Lecture)
Anisa Shaker, Keck School of Medicine of USC, “Epithelial-stromal interactions in the human esophagus.”
Yasuko Iwakiri, Yale University School of Medicine, “The lymphatic vascular system in the liver.
John Chiang, Northeast Ohio Medical University, “Bile acid signaling in gut microbiota and liver metabolism and diseases”
James P. Luyendyk, Michigan State University, “Mechanisms linking blood coagulation to liver injury and regeneration”
Jen-Chywan (Wally) Wang, University of California, Berkeley, “Glucocorticoid-angiopoietin-like 4-ceramide axis and the development of metabolic disorders”
Thomas A. Vallim, University of California, Los Angeles, “Control of liver lipid metabolism by FXR: Challenging the dogma”
Vassilios Papadopoulous, University of Southern California, “Lessons from cholesterol transport in steroidogenesis applied to liver function”
Karen Reue, University of California, Los Angeles, “Viewing obesity and drug-induced diabetes through the lens of sex differences”

Mini-Symposium 2020